tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Quanterix Adopts New Bylaws Amid Financial Challenges

Story Highlights
Quanterix Adopts New Bylaws Amid Financial Challenges

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

An update from Quanterix ( (QTRX) ) is now available.

On August 5, 2025, Quanterix‘s Board of Directors adopted new bylaws to implement a majority voting standard for uncontested director elections. The company also announced financial results for the second quarter of 2025, reporting a revenue decrease of 29% compared to the previous year and a net loss of $30 million. Despite these challenges, Quanterix highlighted significant growth in its Alzheimer’s Diagnostics revenues and strategic actions aimed at long-term growth, including the completion of its acquisition of Akoya Biosciences. The company is focused on achieving cash flow breakeven in 2026 and expects to exit 2025 with approximately $120 million in cash and cash equivalents.

The most recent analyst rating on (QTRX) stock is a Hold with a $8.00 price target. To see the full list of analyst forecasts on Quanterix stock, see the QTRX Stock Forecast page.

Spark’s Take on QTRX Stock

According to Spark, TipRanks’ AI Analyst, QTRX is a Neutral.

Quanterix’s overall score is driven by strong corporate events and strategic initiatives, but is weighed down by weak financial performance and technical indicators. The company’s valuation remains a concern due to negative earnings.

To see Spark’s full report on QTRX stock, click here.

More about Quanterix

Quanterix is a global leader in ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development. The company utilizes its proprietary Simoa® technology to deliver industry-leading sensitivity in detecting and quantifying biomarkers in blood and other fluids. In 2025, Quanterix expanded its portfolio by acquiring Akoya Biosciences, enhancing its capabilities with multiplexed tissue imaging and single-cell resolution, thus advancing precision medicine from discovery to diagnostics.

Average Trading Volume: 752,834

Technical Sentiment Signal: Sell

Current Market Cap: $278.1M

For a thorough assessment of QTRX stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1